We invite you to join us at the upcoming 13th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. The groundbreaking series of Alzheimer's and Parkinson's Diseases Conferences attract international medical and scientific professionals worldwide. The Conference is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases. AD/PDTM Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention and therapy.
The forthcoming AD/PDTM meeting, in 2017 will take place in Vienna, Austria, one of the most classical cities in Europe.
The continuing success of the AD/PDTM meetings is the result of several key ingredients:
A high-quality scientific program covering most recent research, developments, and treatments, with emphasis on overlaps and congruent results among AD, PD and related neurological disorders.
A multidisciplinary mix of participants representing both clinical investigators and basic scientists; as well as both established investigators and young upcoming talents.
An International Scientific Advisory Board covering a broad range of expertise in AD, PD and related neurological disorders.
A concerted attempt to provide an ambiance at the Conference that encourages interaction, exchange of ideas and networking opportunities among all participants.
Travel grants and various awards to junior faculty, postdoctoral fellows, and graduate students, intended to encourage attendance by young scientists at the Conference.
The remarkable success of the series of AD/PDTM Conferences is evident from the progressive increases from one congress to the next, in the number of participants to 3,152 in Nice in 2015, the number of countries represented to 81 in Nice, and the ratio of individuals below the age of 35 to that of the rest of the group. At AD/PDTM 2017 in Vienna we anticipate an attendance of more than 3500 participants.
The reason for this success is the uniqueness of the AD/PDTM meetings, their academic quality combined with the interactive and collegial environment. We believe that there is no other Conference in the world that presents such a high level of science in a condensed manner on one hand, yet on the other hand, provides an enormously comfortable atmosphere in which to enjoy it all.
We invite you to join us at the 13th International Conference on AD and PD, and we hope to welcome you in the Spring of 2017, in beautiful Vienna.
Disease Mechanisms, Pathophysiology
Therapeutic Targets, Mechanisms for Treatment
Drug Development, Clinical Trials
Imaging, Biomarkers, Diagnostics
Genetics, Epidemiology
Cell, Molecular & Systems Biology
Animal Models
Dementia, Cognitive & Motor Dyfunctions
Please read the submission rules before submitting an abstract.
The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission.
The presenting author must be listed as the first author.
Submitted abstracts should include non-published data.
Abstracts previously presented will not be accepted.
All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
Please submit symbols as words.
All abstracts accepted for presentation will be published on the Conference website prior to the Conference.
You may submit more than 1 abstract. However, presenters that are accepted for oral presentation will be permitted to give only 1 oral presentation. Additional accepted abstracts will therefore be poster only.
The abstracts of the Conference will be published online as a supplement to the Neurodegenerative Diseases Journal (NDD) published by S. Karger AG
Please note the submitting author will receive all correspondence about the abstract so we advise that the submitting author details that are entered are the same details as those of the presenting author.
Please ensure that if you are submitting an abstract to be considered for the Young Investigator Award that you upload all relevant supporting documents via the link you will receive in the confirmation e-mail you receive once you final submit your abstract.
Abstracts may not be edited/updated after final submission. You are welcome to bring an updated abstract onsite with you.
Your abstract is not successfully submitted until you receive a confirmation e-mail after clicking the final submit button. If you do not receive a confirmation e-mail, please contact us.
03月29日
2017
04月02日
2017
摘要截稿日期
注册截止日期
2019年03月26日 中国
第14届国际阿尔茨海默病与帕金森病大会2015年03月18日 法国
第12届国际阿尔茨海默病与帕金森病大会
留言